Skip to content

A Descriptive Study on Patients With Bipolar Disorder in Rwanda

A Descriptive Study on Patients With Bipolar Disorder in Rwanda

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04674059
Enrollment
400
Registered
2020-12-17
Start date
2021-01-01
Completion date
2021-12-31
Last updated
2020-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental Disorder, Bipolar Disorder

Brief summary

The aim is to provide a comprehensive assessment regarding the service provision and the accessibility to intensive mental health care in Rwanda

Detailed description

The aim is to provide a comprehensive assessment regarding the service provision and the accessibility to intensive mental health care in Rwanda for patients with bipolar disorder. Knowing about the barriers to treatment, risk and protective factors as well as the current treatment offered for patients with bipolar disorder is essential for the development of therapeutic approaches and improvement in access to care. Up to now, no data on characteristics of patients with bipolar disorder in Rwanda and related risk and protective factors is available. For this purpose, all outpatients with bipolar disorder in Rwanda age \> 18 years, will over a 1-year period be invited to participate in a survey on their experience living with bipolar disorder in Rwanda. Moreover, patients and relatives will be invited for in-depth interviews to explore their perceptions and experiences with the mental health system. Health care providers will meet for focus discussions on to assess the experience, knowledge and practice of caregiving for individuals with bipolar disorder.

Interventions

A questionnaire will be delivered by the health care providers at Ndera Hospital, Kigali, Rwanda or CHUK, Hospital, Kigali, Rwanda. The questions will explore the patient's clinical characteristics, the current treatment and their experience with the mental health care system.

Sponsors

University of Rwanda
CollaboratorOTHER
Mental Health Services in the Capital Region, Denmark
CollaboratorOTHER
University of Aarhus
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* A diagnosis of Bipolar Disorder type I or II that meets DSM-V diagnostic criteria * Age ≥ 18 years

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frameDescription
Diagnoses1 yearPsychiatric diagnoses including both primary diagnosis, secondary diagnosis and somatic comorbidity.
Diagnostic delay1 yearAge of individual at onset of symptoms and age when diagnosed with bipolar disorder.
Number of previous psychiatric hospitalisations1 yearNumerical value of the previous psychiatric hospitalisations.
Number of previous crises1 yearNumerical value of the previous crises defined as an episode of depression or mania or hypomania.
Types of medical treatment provided1 yearWhat type of medical treatment is provided, including brand name, administration and dosage.
Medical Adherence1 yearMedication Adherence Rating Scale (MARS) will be used to assess beliefs and barriers to medication adherence. Total scores on the MARS may range between 0 and 10, with a higher score indicating better medication adherence.
The referral pathways1 yearWho initiated the first contact, who did you seek for help, what kind of help was provided, percent of patients who came in contact with traditional leaders.
Degree of internal stigma1 yearInternalized Stigma of Mental Illness Inventory - 9-item Version (ISMI-9) will be used to assess self-stigma. The resulting score should range from 1 to 4. A score ranging between 1.00-2.50: does not report high internalized stigma vs. a score ranging between 2.51-4.00: indicating high internalized stigma.

Contacts

Primary ContactCaroline J Arnbjerg, Msc
caroline.arnbjerg@ph.au.dk+250786917224
Backup ContactEmmanuel Musoni Rwililiza, Msc
rwimus@gmail.com+250788568244

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026